Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilie Henin

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
British Journal of Clinical Pharmacology|June 27, 2014
Solid oral forms availability in children: a cost saving investigationAudrey Lajoinie, Emilie Henin, Behrouz Kassai, et al.
Advances in Therapy|September 13, 2021
Therapeutic Drug Monitoring Strategies for Envarsus in De Novo Kidney Transplant Patients Using Population Modelling and SimulationsEmilie Henin, Mirco Govoni, Massimo Cella, et al.
The AAPS Journal|January 14, 2016
Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: a Novel Method to Handle the Interval Censoring Caused by Measurement of Smaller TumorsPhilippe B Pierrillas, Michel Tod, Magali Amiel, et al.
The AAPS Journal|June 23, 2016
Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: Handling Sacrifice Censoring and Error Caused by Experimental Measurement on Larger Tumor SizesPhilippe B Pierrillas, Michel Tod, Magali Amiel, et al.
Oncotargets and Therapy|February 23, 2013
Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancerSalima Hamizi, Gilles Freyer, Naoual Bakrin, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 20, 2018
Tumor Growth Inhibition Modelling Based on Receptor Occupancy and Biomarker Activity of a New Bcl-2 Inhibitor in MicePhilippe B Pierrillas, Emilie Henin, Julien Ogier, et al.
Investigational New Drugs|May 27, 2020
Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolationPhilippe B Pierrillas, Emilie Henin, Julien Ogier, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 4, 2019
Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation StrategyPhilippe B Pierrillas, Emilie Henin, Kathryn Ball, et al.
European Journal of Cancer (Oxford, England : 1990)|January 31, 2012
Predictors of prescription errors involving anticancer chemotherapy agentsFlorence Ranchon, Céline Moch, Benoît You, et al.
The FEBS Journal|November 14, 2013
Understanding polyspecificity within the substrate-binding cavity of the human multidrug resistance P-glycoproteinLorena Martinez, Ophélie Arnaud, Emilie Henin, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
British Journal of Clinical Pharmacology|June 27, 2014
Solid oral forms availability in children: a cost saving investigationAudrey Lajoinie, Emilie Henin, Behrouz Kassai, et al.
Advances in Therapy|September 13, 2021
Therapeutic Drug Monitoring Strategies for Envarsus in De Novo Kidney Transplant Patients Using Population Modelling and SimulationsEmilie Henin, Mirco Govoni, Massimo Cella, et al.
The AAPS Journal|January 14, 2016
Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: a Novel Method to Handle the Interval Censoring Caused by Measurement of Smaller TumorsPhilippe B Pierrillas, Michel Tod, Magali Amiel, et al.
The AAPS Journal|June 23, 2016
Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: Handling Sacrifice Censoring and Error Caused by Experimental Measurement on Larger Tumor SizesPhilippe B Pierrillas, Michel Tod, Magali Amiel, et al.
Oncotargets and Therapy|February 23, 2013
Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancerSalima Hamizi, Gilles Freyer, Naoual Bakrin, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 20, 2018
Tumor Growth Inhibition Modelling Based on Receptor Occupancy and Biomarker Activity of a New Bcl-2 Inhibitor in MicePhilippe B Pierrillas, Emilie Henin, Julien Ogier, et al.
Investigational New Drugs|May 27, 2020
Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolationPhilippe B Pierrillas, Emilie Henin, Julien Ogier, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 4, 2019
Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation StrategyPhilippe B Pierrillas, Emilie Henin, Kathryn Ball, et al.
European Journal of Cancer (Oxford, England : 1990)|January 31, 2012
Predictors of prescription errors involving anticancer chemotherapy agentsFlorence Ranchon, Céline Moch, Benoît You, et al.
The FEBS Journal|November 14, 2013
Understanding polyspecificity within the substrate-binding cavity of the human multidrug resistance P-glycoproteinLorena Martinez, Ophélie Arnaud, Emilie Henin, et al.
Pageof 2